BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Chen CH, Chiu YC, Lu SN, Lee CM, Wang JH, Hu TH, Hung CH. Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues. World J Gastroenterol 2014; 20(24): 7686-7695 [PMID: 24976706 DOI: 10.3748/wjg.v20.i24.7686]
URL: https://www.wjgnet.com/1007-9327/full/v20/i24/7686.htm
Number Citing Articles
1
Teresa Broquetas, Montserrat Garcia-Retortillo, Juan José Hernandez, Marc Puigvehí, Nuria Cañete, Susana Coll, Beatriz Cabrero, Maria Dolors Giménez, Ricard Solà, José A. Carrión, Isabelle Chemin. Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analoguesPLOS ONE 2017; 12(11): e0188303 doi: 10.1371/journal.pone.0188303
2
Carla S. Coffin, Kali Zhou, Norah A. Terrault. New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Virus InfectionGastroenterology 2019; 156(2): 355 doi: 10.1053/j.gastro.2018.11.037
3
R. J. Wong, M. T. Nguyen, H. N. Trinh, C. Chan, A. Huynh, M. T. Ly, H. A. Nguyen, K. K. Nguyen, S. Torres, J. Yang, B. Liu, R. T. Garcia, T. Bhuket, R. Baden, B. Levitt, E. da Silveira, R. G. Gish. Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community-based real-world studyJournal of Viral Hepatitis 2017; 24(12): 1089 doi: 10.1111/jvh.12736
4
Joonhong Park, Taewon Bae, Yonggon Cho, Dalsik Kim, Jaehyeon Lee. Analytical Performance of the Sysmex HISCL HBsAg Assay and Comparison with the Roche Elecsys HBsAg II Quant Assay in the Quantification of Hepatitis B Surface AntigenMedicina 2021; 57(12): 1307 doi: 10.3390/medicina57121307
5
Emilia Hadziyannis, Andreas Laras. Viral Biomarkers in Chronic HBeAg Negative HBV InfectionGenes 2018; 9(10): 469 doi: 10.3390/genes9100469
6
Rosa M. Martín Mateos, Víctor F. Moreira Vicente, Eduardo Tavío Hernández, Jose Luis Cuño Roldán, Luis Téllez Villajos, Marta Aicart Ramos, Julia Arribas Anta, Celia Zaera de la Fuente, Agustín Albillos Martínez. ¿Es posible suspender el tratamiento con antivirales orales en los pacientes con hepatitis crónica B antígeno e negativa? Experiencia y nuevas expectativasGastroenterología y Hepatología 2015; 38(5): 305 doi: 10.1016/j.gastrohep.2014.12.001
7
Guan-Huei Lee, David Hsingyu Chen, Seng-Gee Lim. Future Therapy for Hepatitis B Virus: Role of Nucleos(t)ide Analogues and Pegylated Interferon TherapyCurrent Hepatology Reports 2016; 15(4): 230 doi: 10.1007/s11901-016-0325-7
8
Gian Paolo Caviglia, Yulia Troshina, Enrico Garro, Marcantonio Gesualdo, Serena Aneli, Giovanni Birolo, Fabrizia Pittaluga, Rossana Cavallo, Giorgio Maria Saracco, Alessia Ciancio. Usefulness of a Hepatitis B Surface Antigen-Based Model for the Prediction of Functional Cure in Patients with Chronic Hepatitis B Virus Infection Treated with Nucleos(t)ide Analogues: A Real-World StudyJournal of Clinical Medicine 2021; 10(15): 3308 doi: 10.3390/jcm10153308
9
Hemda Schmilovitz-Weiss, Rachel Gingold-Belfer, Alon Grossman, Nidal Issa, Doron Boltin, Yichayaou Beloosesky, Nira Morag Koren, Joseph Meyerovitch, Avraham Weiss, Mark W. Sonderup. Lowering the upper limit of serum alanine aminotransferase levels may reveal significant liver disease in the elderlyPLOS ONE 2019; 14(4): e0212737 doi: 10.1371/journal.pone.0212737
10
Xia-Xia Zhang, Min-Ran Li, Hong-Li Xi, Ying Cao, Ren-Wen Zhang, Yu Zhang, Xiao-Yuan Xu. Dynamic Characteristics of Serum Hepatitis B Surface Antigen in Chinese Chronic Hepatitis B Patients Receiving 7 Years of Entecavir TherapyChinese Medical Journal 2016; 129(8): 929 doi: 10.4103/0366-6999.179802
11
Carla Osiowy, Carla Coffin, Anton Andonov. Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog TherapyCurrent Treatment Options in Infectious Diseases 2016; 8(3): 177 doi: 10.1007/s40506-016-0080-x
12
Yin Wu, Chang Gao, Shaohang Cai, Muye Xia, Guichan Liao, Xiaoyong Zhang, Jie Peng. Circulating miR-122 Is a Predictor for Virological Response in CHB Patients With High Viral Load Treated With Nucleos(t)ide AnalogsFrontiers in Genetics 2019; 10 doi: 10.3389/fgene.2019.00243
13
Ergenekon Karagoz, Alpaslan Tanoglu. Clinical Usefulness of HBsAg Quantification in Patients with Chronic Hepatitis B InfectionHepatitis Monthly 2017; 17(4) doi: 10.5812/hepatmon.36112
14
Xu Li, Qinglong Jin, Hongqin Xu, Zetian Zhang, Hongjie Zhou, Dongqing Yan, Dongmei Li, Pujun Gao, Junqi Niu. Chronic hepatitis B patients with high liver fibrosis levels should receive antiviral treatmentExperimental and Therapeutic Medicine 2017; 13(6): 3624 doi: 10.3892/etm.2017.4422
15
Shirin Demma, Geoffrey Dusheiko. The current treatment situation and definitions of a cure for chronic HBV infectionFuture Virology 2016; 11(1): 79 doi: 10.2217/fvl.15.93
16
Nadia Warner, Stephen Locarnini, Hui Xu. The role of hepatitis B surface antibodies in HBV infection, disease and clearanceFuture Virology 2020; 15(5): 293 doi: 10.2217/fvl-2019-0147
17
Rong-Nan Chien, Jia-Horng Kao, Cheng-Yuan Peng, Chien-Hung Chen, Chun-Jen Liu, Yi-Hsiang Huang, Tsung-Hui Hu, Hwa-I Yang, Sheng-Nan Lu, Yen-Hsuan Ni, Won-Long Chuang, Chuan-Mo Lee, Jaw-Chin Wu, Pei-Jer Chen, Yun-Fan Liaw. Taiwan consensus statement on the management of chronic hepatitis BJournal of the Formosan Medical Association 2019; 118(1): 7 doi: 10.1016/j.jfma.2018.11.008
18
Geoffrey Dusheiko. Current and future directions of management of hepatitis B: steps toward a cureFuture Virology 2018; 13(3): 189 doi: 10.2217/fvl-2017-0103
19
Na Yang, Jin Feng, Taicheng Zhou, Zhuoran Li, Zhengyu Chen, Kaihua Ming, Guangtie Liang, Xiu-xia Lei, Bang-Lao Xu. Relationship between serum quantitative HBsAg and HBV DNA levels in chronic hepatitis B patientsJournal of Medical Virology 2018; 90(7): 1240 doi: 10.1002/jmv.25080
20
Kunal Kerkar, Manisha Tiwari, Dhermendra K. Tiwari, Savita Kerkar. Microbial Products for Health, Environment and AgricultureMicroorganisms for Sustainability 2021; 31: 183 doi: 10.1007/978-981-16-1947-2_8
21
Yi-Cheng Chen, Yun-Fan Liaw. Pharmacotherapeutic options for hepatitis BExpert Opinion on Pharmacotherapy 2016; 17(3): 355 doi: 10.1517/14656566.2016.1118056
22
Cheng-Hsun Ho, Shu-Hui Chen, Hung-Wen Tsai, I-Chin Wu, Ting-Tsung Chang. Fully galactosyl-fucosyl-bisected IgG1 reduces anti-HBV efficacy and liver histological improvementAntiviral Research 2019; 163: 1 doi: 10.1016/j.antiviral.2018.12.021